Jade Biosciences, Inc. (JBIO) Stock

Jade Biosciences, Inc. (JBIO) is a Healthcare stock trading at $16.89 (as of 2026-06-18), with a market capitalization of $1.04B and a trailing P/E of -4.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Valuation — source: SEC EDGAR (first-party)
Price	$16.89
Market Cap	$1.04B
P/E Ratio	-4.6
EV / EBITDA	-5.0
Price / Book	2.80
DCF Value (model)	$-30.96
DCF Upside vs Price	-283.3%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-55.7%
Current Ratio	14.29

Valuation vs Sector & Industry
Stock P/E	-4.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-121.9%
vs Industry	-126.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($99.55M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Tom Frohlich
Employees	50
Country	US
IPO Date	2025-04-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.